Zogenix has completed its rolling submission of a New Drug Application in the US and submitted a marketing application in Europe for Fintepla for the treatment of seizures associated with Dravet syndrome.
Zogenix has revealed top-line results from a second late-stage trial of its investigational Dravet syndrome drug ZX008, showing a significant reduction in seizures.